Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) said that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for its Biologics License Application (BLA). The application sought approval for denileukin diftitox (LYMPHIRTM), a targeted treatment for patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) after prior systemic therapy.

The FDA has requested the addition of enhanced product testing and additional controls, but the federal regulatory agency raised no concerns about the safety and efficacy clinical data or the proposed prescribing information.

$CTXR closed at $1.12, showing a gain of $0.03 (2.75%) on Friday.

In other news, First Solar, Inc. (Nasdaq: FSLR), a leading global provider of solar energy solutions, received a positive boost in its investment outlook as BofA Securities upgraded the company's rating from Neutral to Buy, while raising the price target from $202 to $283.

Based on Friday's closing price of $208.40, the upgraded price target indicates a potential upside of $74.60 or approximately 35.81% for $FSLR, according to the financial advisory firm's view. 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)